Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996-2007

Antiviral Therapy

Volumn 14, Issue 6, 2009, Pages 751-761

  Tashiro, Masato ^a   McKimm Breschkin, Jennifer L ^b   Saito, Takehiko ^a,c   Klimov, Alexander ^d   Macken, Catherine ^e   Zambon, Maria ^f   Hayden, Frederick G ^g  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b CSIRO   (Australia)

^c NATIONAL INSTITUTE OF ANIMAL HEALTH   (Japan)

^d NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^e LOS ALAMOS NATIONAL LABORATORY   (United States)

^f PUBLIC HEALTH ENGLAND   (United Kingdom)

^g UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; ARGININE; ASPARAGINE; ASPARTIC ACID; GLUTAMIC ACID; HISTIDINE; LYSINE; TYROSINE; VALINE; VIRUS SIALIDASE; ZANAMIVIR;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; DRUG USE; HUMAN; IC 50; INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; JAPAN; NONHUMAN; PRIORITY JOURNAL; SEASONAL VARIATION; VIRUS ISOLATION; VIRUS MUTATION;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HUMANS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA, HUMAN; JAPAN; NEURAMINIDASE; SENTINEL SURVEILLANCE;

EID: 72049099839     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1194     Document Type: Article

References (51)

1. Wright P, Neumann G, Kawaoka Y. Orthomyxoviruses. In Knipe DM, Howley PM (Editors). Fields Virology. 5th ed. Philadelphia: Lippincott-Raven Press 2007; pp. 1691-1740.
2. World Health Organization. Pandemic (H1N1) 2009. (Accessed 7 August 2009.) Available from http://www.who. int/csr/disease/swineflu/en/index.html
3. Hayden FG. Pandemic influenza - is an antiviral response realistic? Pediatr Infect Dis J 2004; 23:S262-S269. (Pubitemid 44146422)
4. Gani R, Hughes H, Fleming D, Griffin T, Medlock J, Leach S. Potential impact of antiviral drug use during influenza pandemic. Emerg Infect Dis 2005; 11:1355-1362. (Pubitemid 41209127)
5. Hayden FG. Amantadine and rimantadine - clinical aspects. In Richman DD (Editor). Antiviral Drug Resistance. John Wiley & Sons Ltd 1996; pp. 59-77.
6. Neuraminidase Inhibitor Susceptibility Network. NISN statement on antiviral resistance in influenza viruses. Wkly Epidemiol Rec 2004; 79:306-308.
7. Bright RA, Medina MJ, Xu X, et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005; 366:1175-1181. (Pubitemid 41393595)
8. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA-Express; 2006; 295. (Updated 2 February 2006. Accessed 6 August 2009.) Available from http:// jama.ama-assn.org/cgi/content/abstract/295. 8.joc60020v1
9. Deyde VM, Xu X, Bright RA, et al. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis 2007; 196:249-257.
10. Deyde V, Garten R, Sheu T, Gubareva l, Klimov A. Reply to Saito et al. J Infect Dis 2008; 197:632-633.
11. Centers for Disease Control and Prevention (US). Interim guidance on antiviral recommendations for patients with novel influenza A (H1N1) virus infection and their close contacts. (Updated 6 May 2009. Accessed 7 August 2009.) Available from http://www.cdc.gov/h1n1flu/ recommendations.htm
12. Neuraminidase Inhibitor Susceptibility Network. Use of influenza antivirals during 2003-2004 and monitoring of neuraminidase inhibitor resistance. Wkly Epidemiol Rec 2005; 80:156.
13. Hayden F. Developing new antiviral agents for influenza yreatment: what does the future hold? Clin Infect Dis 2009; 48 Suppl 1:S3-S13.
14. Herlocher ML, Truscon R, Elias S, et al. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis 2004; 190:1627-1630.
15. Yen HL, Herlocher LM, Hoffmann E, et al. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob Agents Chemother 2005; 49:4075-4084.
16. Monto AS, McKimm-Breschkin JL, Macken C, et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 2006; 50:2395-2402.
17. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004; 364:759-765.
18. Ward P, Small I, Smith J, Suter P, Dutkowski R. Oseltamivir (Tamiflu®) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 2005; 55 Suppl 1:i15-i21.
19. McKimm-Breschkin J, Trivedi T, Hampson A, et al. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother 2003; 47:2264-2272.
20. World Health Organization. Influenza A(H1N1) virus resistance to oseltamivir: last quarter 2007 to first quarter 2008. Preliminary summary and future plans. (Updated 13 June 2008. Accessed 6 August 2009.) Available from http:// www.who.int/csr/disease/influenza/oseltamivir-summary/en/ index.html
21. Lackenby A, Thompson CI, Democratis J. The potential impact of neuraminidase inhibitor resistant influenza. Curr Opin Infect Dis 2008; 21:626-638.
22. Wetherall NT, Trivedi T, Zeller J, et al. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J Clin Microbiol 2003; 41:742-750.
23. Buxton RC, Juo RR, Voyta JC, Tisdale M, Bethell RC. Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir. Anal Biochem 2000; 280:291-300.
24. Gubareva LV, Matrosovich MN, Brenner MK, Bethell R, Webster RG. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 1998; 178:1257-1262.
25. Neuraminidase Inhibitor Susceptibility Network. Monitoring of neuraminidse inhibitor resistance among clinical influenza virus isolates in Japan during the 2003-2006 influenza seasons. Wkly Epidemiol Rec 2007; 82:149-150.
26. McKimm-Breschkin JL, Blick TJ, Sahasrabudhe A, et al. Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en. Antimicrob Agents Chemother 1996; 40:40-46. (Pubitemid 26020747)
27. Pediatric Advisory Committee briefing document for Tamiflu. Tamiflu (RO 64-0796) PAC Briefing Document 2008. Hoffman-La Roche 2007; Nutley, NJ, USA. (Updated 20 November 2007. Accessed 6 August 2009.) Available from http://www.fda.gov/ohrms/dockets/AC/07/ briefing/2007-4325b-02-15- Sponsor%20Background%20 Package%20Roche.pdf
28. Ison MG, Gubareva LV, Atmar RL, Treanor J, Hayden FG. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis 2006; 193:760-764.
29. Mishin VP, Hayden FG, Gubareva LV. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob Agents Chemother 2005; 49:4515-4520.
30. Gubareva LV, Kaiser L, Matrosovich MN, Soo-Hoo 30, Hayden FG. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis 2001; 183:523-531. (Pubitemid 32147507)
31. Hatakeyama S, Sugaya N, Ito M, et al. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 2007; 297:1435-1442. (Pubitemid 46556469)
32. World Health Organization. Influenza A(H1N1) virus resistance to oseltamivir - 2008/2009 influenza season, northern hemisphere. (Updated 21 March 2009. Accessed 6 August 2009.) Available from http://www.who.int/csr/ disease/influenza/h1n1-table/en/index.html
33. Lackenby A, Hungnes O, Dudman SG, et al. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill 2008; 13:pii:8026.
34. Sheu TG, Deyde VM, Okomo-Adhiambo M, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 2008; 52:3284-3292.
35. Ives JAL, Carr JA, Mendel DB, et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res 2002; 55:307-317.
36. Le QM, Kiso M, Someya K, et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature 2005; 437:1108. (Pubitemid 41509341)
37. Yen HL, Ilyushina NA, Salomon R, Hoffmann E, Webster RG, Govorkova EA. Neuraminidase inhibitorresistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo. J Virol 2007; 81:12418-12426. (Pubitemid 350085855)
38. Hurt AC, Barr IG, Hartel G, Hampson AW. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir. Antiviral Res 2004; 62:37-45. (Pubitemid 38340746)
39. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza. JAMA 2000; 283:1016-1024.
40. Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza; a randomized controlled trial. Lancet 2000; 355:1845-1850. (Pubitemid 30311875)
41. Whitley RJ, Hayden FG, Reizinger K, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001; 20:127-133. (Pubitemid 32151932)
42. Hayden FG, Belshe R, Villanueva C, et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis 2004; 189:440-449. (Pubitemid 38210580)
43. Hayden FG, Gubareva LV, Monto AS, et al. Inhaled zanamivir for preventing influenza in families. N Engl J Med 2000; 343:1282-1289.
44. Herlocher ML, Truscon R, Fenton R, et al. Assessment of development of resistance to antivirals in the ferret model of influenza virus infection. J Infect Dis 2003; 188:1355-1361. (Pubitemid 37433707)
45. Bouvier NM, Lowen AC, Palese P. Oseltamivir-resistant influenza A viruses are transmitted efficiently among guinea pigs by direct contact but not by aerosol. J Virol 2008; 82:10052-10058.
46. Sugaya N, Mitamura K, Yamazaki M, et al. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin Infect Dis 2007; 44:197-202. (Pubitemid 46079980)
47. Gubareva LV, Webster RG, Hayden FG. Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay. Antiviral Res 2002; 53:47-61.
48. Shiraishi K, Mitamura K, Sakai-Tagawa Y, Goto H, Sugaya N, Kawaoka Y. High frequency of resistant viruses harbouring different mutations in amantadine-treated children with influenza. J Infect Dis 2003; 188:57-61. (Pubitemid 36829742)
49. Ferguson NM, Mallett S, Jackson H, Roberts N, Ward P. A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community based use of antivirals. J Antimicrob Chemother 2003; 51:977-990.
50. Regoes RR, Bonhoeffer S. Emergence of drug-resistant influenza virus: population dynamical considerations. Science 2006; 312:389-391.
51. Lipsitch M, Cohen T, Murray M, Levin BR. Antiviral resistance and the control of pandemic influenza. PLoS Med 2007 4:e15.